Detalles de la búsqueda
1.
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 386(4): 351-363, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34904799
2.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Blood
; 141(16): 1971-1981, 2023 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36626583
3.
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Haematologica
; 109(4): 1194-1205, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37767550
4.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Am J Hematol
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700035
5.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36594167
6.
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Pharm Res
; 37(12): 252, 2020 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33258982
7.
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Lancet Oncol
; 20(7): 998-1010, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101489
8.
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Blood
; 127(1): 79-86, 2016 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26472752
9.
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Blood
; 125(18): 2779-85, 2015 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25769620
10.
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Am J Hematol
; 97(1): E24-E27, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34731510
11.
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Blood
; 133(9): 990-992, 2019 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30593446
12.
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
CPT Pharmacometrics Syst Pharmacol
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38622879
13.
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Adv Drug Deliv Rev
; 207: 115193, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38311111
14.
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Lancet Haematol
; 11(2): e136-e146, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38190832
15.
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Clin Transl Sci
; 16(12): 2744-2755, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37864313
16.
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.
Cancer
; 118(19): 4842-50, 2012 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22434428
17.
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Blood Adv
; 6(2): 533-543, 2022 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34749395
18.
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Lancet Haematol
; 8(12): e891-e901, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34826412
19.
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
Leuk Lymphoma
; 61(12): 2905-2914, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32705923
20.
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
CPT Pharmacometrics Syst Pharmacol
; 9(1): 48-59, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31749251